Utility

Regardless of the exact mechanism(s) mediating the effects of ZKC1, the most effective and least toxic ZKC compound should find a use in the clinics to prevent the loss of body weight i.e. fat (both subcutaneous and visceral) and the skeletal muscle. Treatment of cancer patients with a very cost-effective ZKC compound as an add-on drug is expected to enhance the efficacy of standard cancer treatments and increase the chances of cure and survival.

ZKC compounds on their own also exert significant antitumor effects and, in addition, generally enhance the effects of anticancer drugs (such as cisplatin, cyclophosphamide, and gemcitabine) especially on breast, pancreatic, and ovarian tumors.

Partnership or Sale of the Project

ZKCR is considering two options as to how to proceed with this project:

1. The company would accept partnership proposals to further advance the project resulting in the preparation of a human phase 1 trial. The company has the means, through collaboration with expert laboratories, to perform the required studies at relatively low cost (for example, Institute of Oncology, Budapest).

2. The company would also accept proposals to be bought out, the price matching the research expenses ZKCR spent on the project (about $ 120,00).